findmyKOL

Michael Boland, MD

Enriched profile

Assistant Chief Medical Information Officer, Mass General Brigham; Medical Director of Practice Innovation, Ophthalmology, Massachusetts Eye and Ear; Associate Professor of Ophthalmology, Harvard Medical School · Mass General Brigham

ORCIDNPI
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyOphthalmologyFocusGlaucoma
Active KOLLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Michael Boland is Assistant Chief Medical Information Officer, Mass General Brigham; Medical Director of Practice Innovation, Ophthalmology, Massachusetts Eye and Ear; Associate Professor of Ophthalmology, Harvard Medical School at Mass General Brigham. OpenAlex indexes 283 publications with 5,792 citations (h-index 39); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Michael V. Boland, MD, is Assistant Chief Medical Information Officer, Mass General Brigham. The public record shows 283 publications with 5,792 citations (h-index 39), centered on Glaucoma. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 9 companies.

  • Most recent indexed publication: 2025 · Journal of glaucoma
  • Top research focus: Glaucoma
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma1 trialComa1 trial

Research focus

OpenAlex concept fingerprint
Glaucoma

Drugs & molecules

across trials, industry payments and publications
Durystageneric · BimatoprostClinical trialsIndustry payments11Publications

Works with

trial sponsors and companies reporting payments
Carl Zeiss Meditec, Inc.Clinical trialsIndustry payments14Allergan, Inc.Clinical trialsIndustry payments8Abbvie Inc.Clinical trialsIndustry payments5

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
283publications

Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.

5,792citations

Total citations across indexed works.

39h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    88%
    Prostaglandin Analog37.1%
    Latanoprost96%Travoprost2%Lumigan2%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor22.3%
    Dorzolamide-Timolol76%Dorzolamide Hcl19%Acetazolamide Er6%
    Part D<11 patients
  • Cardiovascular

    10.4%
    Beta blocker10.4%
    Timolol Maleate100%
    Part D59 patients
  • Musculoskeletal

    0.9%
    Cyclooxygenase Inhibitor0.9%
    Ketorolac Tromethamine100%
    Part D<11 patients
1 more therapeutic area behind the reveal.Reveal →
Where care is delivered (Part B)24.9% facility · 75.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/cv/michael-boland-md-ab48792a

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Michael-Boland-2

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net
  • ResearchGate

    researchgate.net/profile/Michael-Boland-6

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    talkingaboutglaucoma.com/guests/michael-boland

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →talkingaboutglaucoma.com
  • Doximity

    Doximity profile (auth-walled, corroborated via SERP snippet as Boston, MA ophthalmology)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Wilmer Eye Institute

    Johns Hopkins University

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org
  • Site Director

    Massachusetts Eye and Ear, Lexington, MA

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.masseyeandear.org
  • Member

    Massachusetts Eye and Ear Glaucoma Center of Excellence

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophai.hms.harvard.edu
2 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.